8-K: ImmunityBio Announces Positive ANKTIVA Trial Results with 71% Complete Response Rate in Bladder Cancer Study

ImmunityBio reports a 71% complete response rate in a 100-patient trial of ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer, with durable responses up to 54 months.

Summary

• ImmunityBio has released new data from its QUILT 3.032 study, which evaluated ANKTIVA in combination with BCG for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (NMIBC CIS).
• The study enrolled 100 patients and achieved a 71% complete response (CR) rate.
• The duration of response in these patients ranged up to 54 months.
• This data will be submitted to the European Medicines Agency (EMA) as part of a Marketing Authorization Application (MAA) in Q4 2024.
• The 71% CR rate is consistent with previous findings reported in the New England Journal of Medicine.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results with a high complete response rate and long duration of response, suggesting a strong potential for the drug. The tone is optimistic and forward-looking, indicating a high level of confidence in the product.

Positives

• The 71% complete response rate is a significant improvement for patients with limited treatment options.
• The durable response, lasting up to 54 months, suggests a long-term benefit for patients.
• The data is consistent with previous findings, reinforcing the therapeutic promise of ANKTIVA.
• The submission to the EMA for marketing authorization is a positive step towards global expansion.

Risks

• The company faces risks related to regulatory submissions and approvals, including the EMA review process.
• There are risks associated with the commercial launch and scaling of manufacturing for ANKTIVA.
• The company's ability to fund ongoing clinical trials and operations is a risk.
• There are risks related to potential product shortages or manufacturing disruptions.

Future Outlook

The company anticipates submitting the data to the EMA in Q4 2024 for marketing authorization and continues to monitor patients to assess the durability of responses and overall survival outcomes. They are also focused on expanding the use of ANKTIVA in other cancer types and developing cancer vaccines.

Management Comments

• Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio, stated that they are encouraged by the consistent complete response rates observed in the expanded patient cohort.
• He also noted that the results highlight the potential of ANKTIVA to transform the treatment landscape for patients with BCG-unresponsive NMIBC CIS, offering hope for improved outcomes and cystectomy avoidance.

Industry Context

This announcement is significant in the context of the bladder cancer treatment landscape, where there is a need for effective therapies for BCG-unresponsive NMIBC CIS. The high complete response rate and durable responses position ANKTIVA as a potential competitor to existing treatments.

Comparison to Industry Standards

• The 71% complete response rate with ANKTIVA is notably high compared to other approved products in this indication, as highlighted by management.
• The duration of response, ranging up to 54 months, is also a significant improvement over many existing treatments for BCG-unresponsive NMIBC CIS.
• While specific competitor data is not provided in this document, the company claims that ANKTIVA achieves one of the highest durable responses compared to other approved products in this indication.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Patients with BCG-unresponsive NMIBC CIS may benefit from a new treatment option with a high complete response rate and durable response.
• The company's employees may be motivated by the positive results and the potential for commercial success.

Next Steps

• The company will submit the data to the European Medicines Agency (EMA) in Q4 2024 for marketing authorization.
• The company will continue to monitor patients to assess the durability of responses and overall survival outcomes.

Key Dates

Keywords

ANKTIVA, ImmunityBio, Bladder Cancer, NMIBC CIS, Immunotherapy, Complete Response, BCG, EMA, QUILT 3.032, IL-15